Core Insights - OPELESIS, a domestic skincare brand, completed its Pre-A round financing at the beginning of this year, with investment from Shunwei Capital, co-founded by Lei Jun and Xu Dalai [1][10] - The brand focuses on light medical beauty skincare, emphasizing technological innovation, and has a research center in Switzerland [1] Financing and Investment - The recent financing will primarily support biomedical research and innovation [3] - Shunwei Capital has invested in over 600 startups since its inception in 2011, with 38 of those companies successfully going public [9] Product Development and Technology - OPELESIS has developed NEUBLOX, a botulinum-like peptide that inhibits dynamic wrinkles with an immediate anti-wrinkle efficiency exceeding 300% compared to ordinary neuropeptides [3][4] - The company has registered 20 products, including skincare and oral health products, with a price range from 12.9 to 549 yuan [6] Market Performance - The projected GMV for OPELESIS on Douyin in 2024 is between 75 million and 100 million yuan, with current GMV ranging from 25 million to 50 million yuan [9] - The brand heavily relies on influencer live-streaming for sales, with over 80% of sales coming from this channel [9] Strategic Partnerships - Following the success of NEUBLOX, OPELESIS has formed a strategic partnership with i+Med to develop injectable biomaterials as a Class III medical device [9] Industry Trends - The light medical beauty market in China has seen a 55% increase in user scale compared to three years ago, with consumers increasingly interested in complex skincare principles [9]